Effects of treatments on cognitive function in patients with idiopathic membranous nephropathy
To Evaluate the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy and Explore the Possible Mechanism by Using Functional Magnetic Resonance Imaging (fMRI)
This study is testing how different treatments for idiopathic membranous nephropathy can affect thinking and memory in patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Beijing Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06245707 on ClinicalTrials.gov |
What this trial studies
This study evaluates how different treatment schemes affect the cognitive function of patients with idiopathic membranous nephropathy, a condition that may lead to cognitive impairment. It employs a prospective, open-label, single-center, randomized controlled design to assess cognitive status before and after treatment. The study also aims to explore the underlying mechanisms of cognitive dysfunction using brain magnetic resonance imaging technology. By addressing a gap in current research, it seeks to provide insights for better treatment strategies and prevention of cognitive decline in affected patients.
Who should consider this trial
Good fit: Ideal candidates include patients with nephrotic syndrome and normal renal function who have been diagnosed with idiopathic membranous nephropathy.
Not a fit: Patients with prior cognitive decline, intracranial diseases, or contraindications for MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies that preserve cognitive function in patients with idiopathic membranous nephropathy.
How similar studies have performed: While there is limited research specifically on cognitive function in idiopathic membranous nephropathy, studies on related conditions have shown varying degrees of success in understanding cognitive impairment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with nephrotic syndrome and normal renal function. * Patients with idiopathic membranous nephropathy diagnosed by pathology. * not received hormone or other immunosuppressive treatment in the past six months. Exclusion Criteria: * Unable to treat patients with hormones and immunosuppression. * Patients with definite intracranial diseases such as previous cerebral infarction and cerebral hemorrhage; * Patients who have been diagnosed with cognitive decline or dementia in the past; * Patients with claustrophobia or have other contraindications for magnetic resonance imaging, such as pacemakers and metal foreign bodies in the body. * Pregnant and lactating women
Where this trial is running
Beijing, Beijing
- Beijing Friedship Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Jia Wang — Student
- Study coordinator: Wenhu Liu
- Email: wenhuliu@mail.ccmu.edu.cn
- Phone: 15110124629
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.